MDXH — MDxHealth S.A.

MDxHealth Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: As reported revenue for Q1 2026 was $27.4 million. On a pro forma basis, excluding the discontinued Resolve UTI business, revenue from core prostate cancer operations was $23.9 million, reflecting an 11% increase year-over-year.
• Gross Profit: Statutory gross profit was $16.6 million; pro forma gross profit (excluding Resolve) was $15 million, resulting in a gross margin of 62.9%, down from 68% in Q1 2025.
• Operating Loss: Statutory operating loss was $7.3 million; pro forma operating loss was $7.9 million, compared to a loss of $4.7 million in the prior year.
• Net Loss: Statutory net loss was $8.9 million; pro forma net loss was $9.4 million, nearly flat compared to $9.3 million in Q1 2025.
• Cash Position: Cash and cash equivalents stood at $43.2 million as of March 31, 2026. After a $15 million earn-out payment, pro forma cash would be $28.2 million.

2. Strategic Updates and Business Highlights

• MDxHealth is focusing exclusively on its core prostate cancer diagnostics, having discontinued the Resolve UTI offering due to reimbursement challenges.
• The integration of the ExoDx business is progressing, with a fully aligned sales force now focused on prostate cancer products (Confirm, GPS, and ExoDx).
• The company is leveraging artificial intelligence (AI) to enhance operational efficiency and clinical value, with ongoing collaborations aimed at developing AI-enhanced diagnostic offerings.

3. Forward Guidance and Outlook

• MDxHealth has updated its 2026 revenue guidance for its core cancer business to $110 million to $115 million, indicating a growth rate of 20% to 26% year-over-year.
• The strategic exit from the Resolve business is expected to streamline operations and improve profitability in the long run.

4. Bad News, Challenges, or Points of Concern

• The decision to discontinue the Resolve UTI business was driven by an unfavorable reimbursement landscape, including a $10.4 million recoupment claim from Novitas, which the company is contesting.
• The transition away from Resolve may have short-term impacts on sales as the sales force adjusts to focusing solely on prostate cancer diagnostics.
• There are concerns regarding declining tissue volume, which has been attributed to integration challenges and customer focus shifts. Management is confident in a rebound but acknowledges the need for continued attention to customer engagement.

5. Notable Q&A Insights

• Management expressed confidence in the clinical validity of the Resolve test despite the reimbursement challenges and is pursuing a formal appeals process.
• The integration of ExoDx is expected to yield operational efficiencies, and management believes the exit from Resolve will ultimately benefit the company's focus and growth trajectory.
• There was acknowledgment of competitive pressures, particularly in the AI space, but management believes their strategic partnerships and internal initiatives will support growth in the GPS and Confirm business lines.
• The company is cautious about cash outlays related to the restructuring of the Resolve business but anticipates that efficiencies will offset these costs.

This summary encapsulates the key points from MDxHealth's Q1 2026 earnings call, highlighting both the positive developments and the challenges the company faces.